1. Home
  2. IFN vs KROS Comparison

IFN vs KROS Comparison

Compare IFN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo India Fund Inc. (The)

IFN

India Fund Inc. (The)

HOLD

Current Price

$13.78

Market Cap

576.5M

Sector

Finance

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$21.01

Market Cap

655.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFN
KROS
Founded
1993
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
576.5M
655.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
IFN
KROS
Price
$13.78
$21.01
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$22.20
AVG Volume (30 Days)
135.2K
790.2K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
8.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.57
Revenue
N/A
$246,718,000.00
Revenue This Year
N/A
$6,924.79
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.35
Revenue Growth
N/A
37798.31
52 Week Low
$14.40
$9.12
52 Week High
$21.25
$22.55

Technical Indicators

Market Signals
Indicator
IFN
KROS
Relative Strength Index (RSI) 38.19 61.60
Support Level $13.46 $19.76
Resistance Level $13.98 $21.76
Average True Range (ATR) 0.16 0.82
MACD 0.05 -0.12
Stochastic Oscillator 61.54 46.59

Price Performance

Historical Comparison
IFN
KROS

About IFN India Fund Inc. (The)

India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: